Nishioka K, Matsunaga T, Katayama I
Department of Dermatology, Tokyo Medical and Dental University, School of Medicine, Japan.
J Dermatol. 1995 Mar;22(3):181-5. doi: 10.1111/j.1346-8138.1995.tb03367.x.
Recombinant gamma interferon (IFN-gamma) was employed to treat adult-type atopic dermatitis. Eight cases received subcutaneous injections of 500,000 JRU of IFN-gamma for 8 weeks. They responded relatively well to this treatment; however, the overall response to the treatment was not significantly better than that to conventional therapy in the control group. There was no significant suppression of itch or erythema. Swelling was reduced at the 8th week in the treatment group. Frequency of flushing attacks on the face was reduced and disappeared within four weeks in 6 of these patients; however, a similar reduction of frequency was observed in the control group. Papular and lichenified lesions on the trunk and extremities responded significantly to the treatment later than 5 weeks after its initiation. Serum IgE level was not affected by the treatment. Seven had the same level of serum IgE before and after the treatment. The serum cytokine level in the treated patients was also unaltered. Therefore, although IFN-gamma treatment has some benefit in the treatment of severe cases of atopic dermatitis, it should be applied to limited cases because of its high cost.
重组γ干扰素（IFN-γ）被用于治疗成人型特应性皮炎。8例患者接受皮下注射500,000 JRU的IFN-γ，疗程为8周。他们对这种治疗反应相对良好；然而，总体治疗反应并不比对照组的传统疗法显著更好。瘙痒或红斑没有得到明显抑制。治疗组在第8周时肿胀减轻。这些患者中有6例面部潮红发作频率降低，并在四周内消失；然而，对照组也观察到了类似的频率降低。躯干和四肢的丘疹及苔藓化皮损在治疗开始后5周后对治疗才有明显反应。血清IgE水平不受该治疗影响。7例患者治疗前后血清IgE水平相同。治疗患者的血清细胞因子水平也未改变。因此，尽管IFN-γ治疗在重度特应性皮炎治疗中有一定益处，但因其成本高昂，应仅应用于有限的病例。
